Concepedia

Jill Hallin

JH

24

Publications

5K

Citations

21

H-Index

2008

Active since

Affiliations

Mirati Therapeutics (United States)(Current)

Pfizer (United States)

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Harvard University

Jill Hallin is an author at Mirati Therapeutics (United States) specializing in medicine, tumor biology, and cancer research.

ORCID

Top concepts

Publications per year

2008–2025

24

Publications

24

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.2K citations · Full text

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 644 citations · Full text

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 559 citations · Full text

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 465 citations

, , +7

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah Cheng, Nune Markosyan et al. · Cancer Discovery · 2022 · 329 citations · Full text

Rows per page

1–5 of 24